DRD2 and neuroendocrine neoplasm: DR polymorphisms have been linked to an increased risk of non‐small‐cell lung cancer and gastric cancer, while heightened expression of dopamine D2 receptors (DR2) has been observed in various cancer types such as gastric cancer, neuroendocrine tumors, glioma, and breast cancer.33